SynGenSys applies computational design strategies to engineer synthetic promoters with predictable performance characteristics for therapeutic and manufacturing applications. Professor David James ...
Learn how synthetic promoters bring innovation to gene expression, enhancing performance and safety in biotechnology ...
GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to ...
Carbone called BAP1 a “paradox” because of its seeming ability to both promote and slow cancer, depending on the ...
Biomarker data for Sarepta Therapeutics’ RNA programs, licensed from Arrowhead Pharmaceuticals, are “competitive” and “strong ...
Prestigious Publication Reinforces risto-cel’s Durable, Differentiated Clinical Data for the Treatment of SCD with Severe ...
Morning Overview on MSN
RNA-guided CRISPR tool turns genes on with dose control
Researchers have built a series of CRISPR-based platforms that can switch endogenous genes on and, just as critically, dial ...
FDA alignment achieved on pivotal study design supporting a planned Biologics License Application (BLA) submission -- 30-patient pivotal study initiated, evaluating seizure reduction and ...
From legacy therapeutics to next-generation GLP-1s, advances in synthesis, analysis, and regulation are reshaping how peptide ...
Rocket Pharmaceuticals (RCKT) stock surged 9% after FDA approved KRESLADI, the first gene therapy for severe LAD-I in ...
Soy Carmín on MSN
15 resveratrol-rich foods and lifestyle habits that truly support your skin from within
The secret to healthy skin isn't just in creams: 15 foods with resveratrol and key habits you should integrate into your ...
Rocket Pharma receives US FDA approval of Kresladi for paediatric patients with severe leukocyte adhesion deficiency-I: Cranbury, New Jersey Saturday, March 28, 2026, 15:00 Hrs [I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results